Highlights Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Market Closed - Hong Kong S.E. Other stock markets 04:08:20 2024-04-26 am EDT			5-day change	1st Jan Change
2.72 ^HKD	+0.74%		+4.21%	-27.08%

Mar. 27	Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 07	Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Luye Pharma Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Luye Pharma Group Announces the Launch of Its Innovative Drug Zepzelca® (Lurbinectedin) for the Treatment of SCLC in Both Hong Kong and Macao	Mar. 06	CI
Luye Pharma Group Ltd. Announces First Patient Enrolled for Phase 3 Clinical Study of the Group's Innovative Formulation LY01610	Mar. 04	CI
Luye Pharma Group Ltd. Provides Updated Progress in Relation to the Marketing Review of Paliperidone Palmitate Extended-Release Injectable Suspension in the United States	Feb. 01	CI
Luye Pharma's Small Cell Lung Cancer Treatment Secures Hong Kong Marketing Approval	Dec. 13	MT
Luye Pharma Group Ltd. Announces Innovative Drug Lurbinectedin Receives Approval for Marketing in Hong Kong	Dec. 12	CI
Pharma Mar Partner Wins Approval for Lung Cancer Drug in Macao	Dec. 04	MT
Luye Pharma Group Ltd. Announces Rivastigmine Twice Weekly Transdermal Patch Approval for Marketing in China	23-10-31	CI
Luye Pharma Group Ltd. Submits New Drug Application to the U.S. Food and Drug Administration Through the 505(B)(2) Pathway for Paliperidone Palmitate Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder	23-10-09	CI
Luye Pharma Group Ltd. Announces the Innovative Formulation, Goserelin Microspheres for Injection Approved by the National Medical Products Administratio	23-09-07	CI
Luye Pharma Group Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
Luye Pharma Group Ltd. Submits New Drug Application for Lurbinectedin	23-08-21	CI
Luye Pharma Group Ltd. Announces the First Batch of Rykindo for Extended-Release Injectable Suspension for Export to the United States	23-08-17	CI
Chinese Regulator Accepts Luye Pharma's New Drug Application for Parkinson's Disease Injectable	23-08-01	MT
Luye Pharma Group Ltd. Announces Acceptance of the NDA and Priority Review for Rotigotine Extended-Release Microspheres for Injection by National Medical Products Administration	23-08-01	CI
Luye Pharma Group Ltd. Completes Patient Enrollment for the Phase 2 Clinical Trial of New Class 1 Drug LY03014 in China	23-07-06	CI
Luye Pharma Group Ltd. Announces National Medical Products Administration of People's Republic of China Approves its Goserelin Microspheres for Injection for Treatment of Prostate Cancer for Patients Requiring Androgen Deprivation Therapy	23-07-04	CI
Luye Pharma Group Ltd. Announces Marketing Registration of Xuezhikang Approved in Uzbekistan	23-06-08	CI
Luye Pharma Group Ltd Announces Acceptance of the NDA for Lurbinectedin by NMPA in China	23-06-06	CI
Shandong Boan Biotechnology Enters Rent Sharing Agreement with Affiliate for US Premises	23-04-05	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Luye Pharma Group Ltd.

Equities

2186

BMG570071099

Highlights

Filters